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The insulin-dependent diabetic syndromes of the BB rat and man have several
characteristics in common that implicate autoimmune processes in the etiology
of pancreatic a cell destruction. The main arguments in favor of this are early
infiltration of the islets by mononuclear cells (1, 2), and the presence of islet cell
cytoplasmic (ICA)' and surface autoantibodies (ICSA) (3). ICSA are immunocy-
tochemically detectable in the sera ofpatients withrecent onsetinsulin-dependent
diabetes mellitus (IDDM) and also in newly diagnosed diabetic BB rats. In vitro,
ICSA can be cytotoxic for a cells (4-6), suggesting that these circulating auto-
antibodies may be direct effectors ofa cell destruction in IDDM. However, what
role they actually play in causing islet cell damage is still not completely clear.
From this point of view it would be of interest to characterize (3 cell-specific
autoantigens recognizedby ICSA. Effortshave been made toisolate autoantigens
using patient sera (7, 8) and mAbs against islets (9-11) . In this study we describe
the successful preparation by hybridoma technology of a complement-mediated
cytotoxic monoclonal autoantibody from a diabetic BB rat that reacts with rat
insulinoma cells (RINm5F) and primary rat islet cells. The functional properties
ofthis antibody and the antigens to which it binds are defined.
Materials and Methods
Materials.
￿
Reagents were obtained from the following sources: trypsin/versene solu-
tion from Biofluids Inc. (Rockville, MD); o-phenylenediamine dihydrochloride (OPD)
from Sigma Chemical Co. (St. Louis, MO); polyethylene glycol 1000 from J. T. Baker
Chemical Co. (Phillipsburg, NJ). Antilg reagents were obtained from CooperBiomedical,
Inc., (Malvern, PA) and Kirkegaard & Perry Laboratories (Gaithersburg, MD); rabbit
complement (Low-Tox-H) was from Accurate Chemical & Scientific Corp. (Westbury,
NY); bovine testes hyaluronidase and Vibrio cholerae neuraminidase were from Behring
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'Abbreviations used in this paper:
￿
ICA, islet cell cytoplasmic autoantibodies; ICSA,islet cell surface
autoantibodies; IDDM, insulin-dependent diabetes mellitus; OPD, o-phenylenediamine dihydrochlo-
ride.
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Diagnostics (San Diego, CA); Clostridium perfringens neuraminidase (Type VI) from Sigma
Chemical Co. ; collagenase from Wako Pure Chemical Industries (Osaka, Japan). BB rats
were kindly supplied by Professor A. A. Like (University of Massachusetts Medical School,
Department of Pathology, Worcester, MA). The HL-60 human promyelocytic leukemia
cell line, rat fibroblast cell line, rat testicular Leydig cell line (LC540), rat pituitary tumor
cell line (GH3), and rat basophilic leukemic cell line (2H3) were obtained from the
American Type Culture Collection (Rockville, MD). The rat insulinoma cell line
(RINm5F) was established by Gazdar et al. (12).
Carbohydrates were obtained as follows: a-lactose, lactulose, D-galactose, a-D-glucose,
a-methyl-D-galactoside, fl-methyl-D-galactoside, p-nitrophenyl-a-D-galactoside, p-ni-
trophenyl-,B-D-galactoside, lactobionic acid were purchased from Sigma Chemical Co.; N-
acetyl-lactosamine was from E-Y Laboratories, Inc. (San Mateo, CA); and ganglioside GM,
from Supelco, Inc. (Bellefonte, PA). Insoluble immunoadsorbents (Synsorbs), coupled to
monosaccharides and disaccharides, were a gift from D. Baker, Chembiomed Ltd. (Ed-
monton, Alberta, Canada). The glycolipids lactosyl ceramide, ceramide trihexoside, glo-
boside, paragloboside, and (a2-3)sialosylparagloboside were isolated and purified from
human red blood cells as previously described (13-15). The ganglioside (a2-6)-
sialosylparagloboside was isolated from human meconium by the procedure described by
Nilsson et al . (16). Asialo GM, was prepared from GM, by mild acid hydrolysis. Lacto-N-
fucopentaosyl III ceramide and the H, blood group active glycolipid were gifts from D.
Zopf (Bethesda, MD) and S. Hakomori (Seattle, WA), respectively. Glycolipids were also
isolated from the HL-60 and RINm5F cell lines by extraction with chloro-
form/methanol/water 4:8 :3 (17).
Isolation ofPancreatic Islets and Preparation ofSingle Cell Suspensions.
￿
Pancreatic islets
of Langerhans were isolated by collagenase digestion (18) from 200-250 g male WF rats
that were fed ad libitum. The islets were dissociated by gentle pipetting in a trypsin/versene
solution (19). ^"60% of the single cells were 3 cells by immunofluorescence staining with
fluorescein-conjugated antiinsulin antibody.
Production of mAbs.
￿
Spleen cellsof newly diagnosed BB rats were harvested within 20
d of onset of glycosuria and fused with the mouse myeloma cell line P3x63Ag8.653 by
a modification of the procedure described by Kohler and Milstein (20). The fusion
was carried out in the presence of 50% PEG 1000 at neutral pH at a ratio of
spleen cell/myeloma cell of 4:1 . After fusion, cells were resuspended in hypoxan-
thine/aminopterin/thymidine medium and seeded at 2 X 105 cells per well in 96-well
tissue culture plates. When the hybridomas reached confluence, supernatants were tested
for Ig production. Hybridomas producing autoantibodies were cloned twice by limiting
dilution (21). Resident peritoneal macrophages from BALB/c mice, collected after inject-
ing 5 ml of PBS, were used as feeder cells (5 X 10' cells/well).
Detection of Antibodies.
￿
Hybridoma supernatants were screened for rat Ig (IgG and
IgM) production by an ELISA as follows: Immulon II plates (Dynatech Laboratories, Inc.,
Alexandria, VA) were coated with 0.5 wg/100 y1/well of goat anti-rat IgG (H and L
chain-specific) in 0.05 M carbonate/bicarbonate buffer (pH 9.6) overnight at 4 °C. The
remaining incubations were at room temperature. After five washes with PBS containing
0 .05% Tween 20 (PBS/Tween), the wells were incubated for 1 h with 100 Al of hybridoma
supernatants, washed five times with PBS/Tween, and then incubated with 100 A,1 of a
1 :400 dilution of peroxidase-conjugated goat anti-rat IgG and anti-rat IgM for 1 h. After
five washes with PBS/Tween, 100 Al of OPD solution was added to each well (22). The
OD was read with a microtiter reader (Flow Laboratories, Inc., McLean, VA) after 30
minute incubation .
5' Cr-release Cytotoxicity Assay.
￿
The "Cr-release cytotoxicity assay was performed as
follows (23). All incubations were conducted at 37°C. Cells at ^-90% confluence in 96-
well tissue culture plates were incubated with 100 Al of culture medium containing 1 ACi
of"Cr-sodium chromate per well for 5 h. The cultures were gently washed and incubated
with 100 Al of hybridoma supernatants for 1 h. The supernatants were removed and the
cultures were washed and incubated for 45 min with 100 AI of a 1 :5 dilution of rabbit
complement in HBSS or buffer control. Aliquots (80 Al) from each reaction mixture were126
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removed and counted in a model 9000 gamma counter (Beckman Instruments, Inc.,
Fullerton, CA). A rabbit hyperimmune serum directed against rat islets served as a positive
control. For cells in suspension, 5-10 X 105 cells/100,a1 were incubated at 37°C for 5 h
with 1 uCi of "Cr-sodium chromate in a microtube. For isolated rat islet cells, 2 X 104
cellswere first cultured for 24 h and then incubated at 37°C for 3 h with 10 'UCi of
5`Cr-
sodium chromate (24). In some experiments, cells were treated with neuraminidase after
"Cr labeling. For neuraminidase-treated cells, rabbit complement was preabsorbed with
neuraminidase-treated RINm5F cells (5 X 107 cells/vial) for 2 h in ice and then was used
at a 1 :5 dilution . Results given are the average of duplicate determinations and are
representative of two or more experiments. The percent "Cr release was determined by
the following equation: % "Cr release = 100 X [("Cr release in presence of supernatant
+ complement) -
(5 'Cr release with complement alone)]/[(total "Cr release by Triton X-
100) - ("Cr release with complement alone)]. Release in the absence of antibody was
<10% of total "Cr release.
Enzyme Treatment of Cells.
￿
To disperse cells from tissue culture flasks, the cultures
were gently washed twice with PBS and incubated in PBS without Ca" and Mg". After
30 min, cells were easily detached from tissue-culture flasks. Cells were washed twice with
PBS, resuspended to 2-5 x I0'/ml in the appropriate buffer with or without enzyme (V.
cholerae neuraminidase, 5-200 AU/ml, in HBSS or trypsin, 0.1 %-0.5%, or hyaluronidase,
0.2%, both in PBS) and incubated for 1 h at 37'C.
Indirect Immunofuorescence. Cells dispersed from tissue culture flasks were resus-
pended to 2-5 X 106/tube, and incubated with 100 ttl of hybridoma culture supernatants.
After washing, these cells were incubated with 5 pl of fluorescein-conjugated goat anti-
rat IgM (A chain-specific) for 1 h. All incubations were at room temperature .
Fresh-frozen sections of BB rat and blood group O human pancreatic tissues were also
used for indirect immunofluorescence. Sialic acid was removed by incubations with 5
,uU/ml V. cholerae neuraminidase in HBSS for 1 h at 37°C. After extensive washing in
PBS, the sections were incubated with hybridoma culture supernatants for I h at 37 °C,
washed, and then incubated with an appropriate dilution offluorescein-conjugated F(ab')2
fragments ofgoat anti-rat IgM. Culture supernatant of the fusion partner and rat gamma-
globulin (20 tug/ml) were used as controls.
Iodination.
￿
100 wg of antibody in 100 ttl PBS and 0.3 mCi Na '251 were incubated for
5 min at room temperature in tubes coated with 20,ug of Iodogen (25). The mixture was
applied to a PD-10 column (Pharmacia Fine Chemicals, Piscataway, NJ) equilibrated with
0.1 % gelatin in PBS. The void volume was dialyzed against PBS .
Immunostaining of Glycolipids.
￿
The method was previously described (13, 26). All
incubations were at room temperature. Briefly, glycolipids were chromatographed on
high-performance thin-layer chromatography plates in chloroform/methanol/0.25%
aqueous KCI, 5:4:1 . After drying, the plates were soaked in 0.1 % poly (isobutylmethac-
rylate) in hexane for 90 s. After drying, the plates were sprayed briefly with PBS and
then incubated in Tris/BSA (0.05 M Tris, 0 .15 M NaCI, pH 7.8, with 1 % BSA, and 0.1
sodium azide) for 45 min to decrease nonspecific binding of antibody. The plates were
overlaid with 60 ,ul/cm2 of a 1 :5 dilution in Tris/BSA of hybridoma culture supernatant
for 1 h. After washing five times in PBS, the plates were overlaid with a dilution of
1151_
labeled goat anti-rat IgM in Tris/BSA (2 X 106 cpm/ml). After a 1-h incubation, the
plates were washed in PBS, dried under a heat lamp, and exposed to x-ray film overnight.
In some experiments, the chromatography plates were treated with neuraminidase as
follows. After the 45-min incubation in Tris/BSA to block nonspecific binding, the plates
were washed three times in 0.05 M sodium acetate, 0.15 M NaCl, 0 .009 M CaCl2, pH
5.5. The plates were then overlaid with 0.2 U/ml of C. perfringens neuraminidase in this
buffer or with buffer alone. After an overnight incubation at room temperature, the
plates were washed five times in PBS and the assay was completed as above.
Radioimmunoassays.
￿
The method was similar to those previously described (13, 27).
All assays were performed in triplicate at room temperature in 96-well flat-bottomed
polyvinylchloride microtiter plates. We added 20 Al of a solution of glycolipid in methanol
to each well . This was allowed to dry by evaporation. The wells were filled with Tris/BSAUCHIGATA ET AL. 127
and incubated for 45 min to decrease nonspecific antibody binding. The wells were
emptied and 50 A,1 of a 1 :5 dilution of hybridoma culture supernatant in Tris/BSA was
added. After a 1 h incubation, the wells were washed three times with Tris/BSA, and 50
Al (100,000 cpm) of ' 251-labeled anti-rat IgM diluted in Tris/BSA was added to each well.
Aftera 1-h incubation, the wells were washed five times with PBS, cut out, and counted
in a model 1272 gamma counter (LKB Instruments, Inc., Gaithersburg, MD). The
coefficient of variation for these assays is <10%.
Hapten Inhibition Studies.
￿
Several carbohydrates were tested for their ability to inhibit
binding of mAb E5C2 to its target antigen. Each microtiter plate well was coated with
crude glycolipids isolated from 2 X 106 HL-60 cells. A 1 :10 dilution of antibody E5C2 in
Tris/BSA was incubated at room temperature for 1 h with varying concentrations of
these carbohydrates. The absorbed antibody solution was then tested by the RIA described
above. Typically, when no inhibiting carbohydrate was used,
￿
3,000 cpm of
1251 bound
to the well.
Adsorption studies with the insoluble immunoadsorbents were performed as described
previously (28). A 1 :16 dilution of E5C2 antibody in Tris/BSA was incubated with 50
mg/ml of Synsorbs. The mixture was gently rotated for one hour at room temperature,
centrifuged briefly to sediment the Synsorbs, and the supernatant was tested by RIA
exactly as above.
Western Blot Analysis.
￿
Cell cultures were washed twice with PBS and the cells were
scraped from the flasks. The flasks were washed twice with PBS containing 1 % NP-40
and 2 mM PMSF. The cell suspension was kept on ice for 30 min and then homogenized
with a 10 Broeck tissue grinder. Aliquots of homogenate were either used immediately
or stored at -20°C. Before use, the samples were centrifuged for 1 min in an Eppendorf
microtube, and the protein content of the supernatant was determined (29). Aliquots of
the supernatant were mixed with an equal volume of application buffer to yield final
concentrations of 10% glycerol, 5% mercaptoethanol, 2.3% SDS, and 0.0625 M Tris (pH
6.8). The mixture was heated in a boiling water bath for 2 min. SDS-PAGE was performed
using an 11% gel under reducing conditions (30). Aliquots of supernatant in application
buffer were applied to each lane. Prestained molecular weight standards, 14,300 to
200,000 mol wt (Bethesda Research Laboratories, Bethesda, MD), were run in each gel.
After electrophoresis, the gels were blotted onto nitrocellulose paper at 10° C for 90 min
at 90 V (31) using a Biorad Transblot System (Bio-Rad Laboratories, Richmond, CA).
The blots were cut into strips; some were stained with amido-black, while others were
incubated overnight at room temperature in PBS containing 0.5% gelatin and 0.02%
NaN3 to blockresidual protein-binding sites. The blocked strips were incubated overnight
in 0.05 M sodium acetate, 0 .15 M NaCl, 0.009 M CaCl2, pH 5.5, with or without 0.1
U/ml V. cholerae neuraminidase. They were then washed five times with PBS containing
0.1% gelatin, 0.05% Tween 20 and 0.02% NaNS (washing buffer). The blots were
immunostained with culture supernatant containing mAb E5C2; the culture supernatant
of the fusion partner was used as a control. Tris, Tween 20, and NaN3 were added to
those supernatants to yield finalconcentrations of 50 mM, 0.05%, and 0.02%, respectively,
at pH 7.4. After overnight incubation at room temperature, the blots were incubated for
2 h at room temperature with 300,000 cpm/ml of 1251-labeled goat anti-rat IgM in
washing buffer. Afterfive washes, the blots were exposed to x-ray film with an enhancing
screen overnight at -70°C.
Results
Production of mAb E5C2.
￿
Spleen cells from newly diagnosed BB rats (killed
within 20 d after onset of glycosuria) were fused with the myeloma cell line
P3x63Ag8 .653 . Initial screening of culture supernatants from the resulting
hybridomas was performed by solid-phase ELISA. ^-90% of the 70,000 wells
tested yielded hybridomas of which 10% produced rat IgG or IgM. Supernatants
from >6,000 wells containing rat IgG or IgM were tested for cytotoxicity against
rat insulinoma cells (RINm5F) using the
51Cr-release cytotoxicityassay. 17 wells128
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TABLE I
s' Cr Releasefrom LabeledRat Cells by mAbs
* RINm5F, rat insulinoma cells; LC540, rat Leydig cell tumor cells; GH3, rat pituitary tumor cells;
2H3, ratbasophilic leukemic cells.
653 is thecontrol supernatant from the P3 x 63 Ag8.653 fusion partner.
TABLE 11
Binding ofE5C2 to Viable RINm5F and Viable Primary RatIslet
Cells: Effect ofNeuraminidase
were positive and 9 clones were established from these after two cloning steps
(Table I). The antibody produced by one clone, E5C2, was only cytotoxic for
RINm5F cells and not for four other rat cell lines (i.e., testicular Leydig cell line
[LC540], pituitary tumor cell line [GH3], basophilic leukemia cell line [2H3],
fibroblasts) orfornormal spleen cells. The othereight clones were notspecifically
cytotoxic for RINm5F cells (Table I). The isotype of E5C2 was identified as
IgMK by solid-phase ELISA. E5C2 was used in all subsequent experiments.
Enzyme Treatment of RINm5F Cells, Primary Islet Cells, and Normal Pancreas
To investigate the nature of the antigen recognized by E5C2, viable RINm5F
cells were treated with a variety of enzymes. Whereas only 5% of untreated
RINm5F cells showed a strong pattern of surface immunofluorescence after
exposure to E5C2, 75% of the neuraminidase treated cells (5 uU/ml) showed
strong surface immunofluorescence after exposure to E5C2 (Table II). Hyalu-
ronidase and trypsin did not increase antibody binding nor did fixation with
paraformaldehyde (data not shown). This suggests that most of the antigen
recognized by E5C2 is hidden on RINm5F cells by sialic acid residues. Viable
primary rat pancreatic islet cells were also tested by indirect immunofluorescence
with E5C2. No staining was evident without neuraminidase treatment (Fig. 1, A
and B). After neuraminidase treatment, however, 45% of cells were stained by
E5C2 (Table II). None of the insulin-negative cells were stained by E5C2 (data
not shown), whereas 75% ofinsulin-positive cells were stained (Fig. 1, B and C).
Cell lines*
Percent"Cr release by mAbs:
E5C2 C3B2 D7G7 D9C4 G4D2 D2B3 D10D9 G4E10 C3F5 653$
RINm5F 63 76 45 80 51 90 37 43 70 0
LC540 5 87 100 85 100 100 46 24 100 0
GH3 6 4 23 9 12 8 11 40 9 7
Fibroblast 0 53 51 33 23 32 94 58 74 0
2H3 0 ND ND ND ND ND ND ND ND 0
Spleen cells 2 ND ND ND ND ND ND ND ND 0
Treat-
ment of
cellswith
neura-
minidase
Antibody Inhibitor
Percent
cellsby
RIN-
m5F
cence
positive
indirect
immunofluores-
Primary
islet cells
- E5C2 None 5 0
+ E5C2 None 75 45
+ E5C2 Lactose (200 mM) 0 0UCHIGATA ET AL.
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FIGURE 1 .
￿
Binding of antibody E5C2 to rat and human islet cells by indirect immunofluo-
rescence . Viable islet cells and frozen sections of pancreas were prepared and stained with
E5C2 as described in Materials and Methods . (A) Viable primary rat islet cells, untreated,
stained with E5C2 (X 254) ; (B) viable primary rat islet cells treated with neuraminidase and
stained with E5C2 (X 254); (C) cells inB fixed in 1% paraformaldehyde and then stained with
antiinsulin antibody (X 254) . The same cells were examined in B and C. (D) Section of rat
pancreas, untreated, stained with E5C2 (X 134); (E) section of rat pancreas, neuraminidase-
treated, stained with E5C2 (X 134) ; (F) section of human pancreas, untreated, stained with
E5C2 (X 134) ; (G) section of human pancreas, neuraminidase-treated, stained with E5C2 (X
134) .
E5C2 did not stain frozen sections of untreated pancreatic tissue (Fig . 1, D and
F), but stained both rat and human pancreatic islets after neuraminidase treat-
ment (Fig . 1, E and G) . Similar results were obtained with frozen sections of
monkey pancreas (not shown) . This strongly suggests that the E5C2 antigen is130
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TABLE III
RINm5F andPrimary RatIslet Cells Treated with Neuraminidase
and Exposed to E5C2 and Complement
Treatment ofcells
with neuraminidase
Percent "Crrelease
RINm5F
￿
Primary islet cells
present in normal pancreatic islets, but is hidden by sialic acid residues. Rat
kidney glomeruli were also stained by E5C2 after neuraminidase treatment, but
other rat tissues (e.g., endocrine, nerve, liver, and muscle) were not stained with
or without neuraminidase treatment.
Since neuraminidasetreatment exposesthe E5C2 antigen not only on RINm5F
cells, but also on primary islet cells, the effect of neuraminidase treatment on
E5C2-induced cytotoxicity was investigated. RINm5F cells and primary rat islet
cells were labeled with 51Cr, treated with neuraminidase, and subjected to the
complement-mediated cytotoxicity assay described above. E5C2 was cytotoxic
for RINm5F cells before and after neuraminidase treatment (Table III). In
contrast, E5C2 was not cytotoxic for primary rat islet cells before neuraminidase
treatment, but was cytotoxic after neuraminidase treatment. LC540, GH3, and
rat fibroblasts were not rendered susceptible to E5C2-mediated cytotoxicity by
neuraminidase treatment (data not shown).
Characterization of the Antigen Recognized by E5C2.
￿
Since neuraminidase treat-
ment increased binding of E5C2 to both RINm5F cells and primary islet cells by
indirect immunofluorescence, this suggested that antibody binding was blocked
by the presence of sialic acid residues. This could be due to sialic acid covalently
bound to a carbohydrate antigen or to the presence of sialic acid on neighboring
nonantigenic molecules. The former possibility was tested using glycolipids
isolated from the RINm5F cell line. Total glycolipids from RINm5F cells, HL-
60 cells, and a ganglioside-enriched fraction from human RBCs were separated
by thin-layer chromatography. The chromatograms were exposed to neuramin-
idase or to buffer and then immunostained with E5C2-containing culture super-
natant (Fig. 2). No binding of E5C2 to untreated RINm5F glycolipids was found
(Fig. 2 A). The faint staining near the top of lane A is artifactual . However, a
band was identified at the origin after neuraminidase treatment (Fig. 2 B,
arrowhead). Since a crude lipid extract was used, this band could represent a
glycoprotein antigen(s) that is relatively soluble in organic solvents. It could also
represent a glycolipid(s) with a large oligosaccharide moiety (15-20 sugars). In
contrast, two distinct doublets were found with untreated HL-60 cells (Fig. 2C),
and several additional bands were revealed by neuraminidase treatment (Fig.
2D). Glycolipids with identical sugar sequences often occur in doublets due to
differences in the ceramide moiety. Similar findings were obtained with the
human RBC extract (Fig. 2, E and F). Further experiments showed that the
binding of E5C2 was directly proportional to the antibody concentration (Fig.
3). To confirm that these findings were due to antibody binding, purified E5C2
(10 hg/ml) was used. Identical results to those seen in Fig. 2 were obtained. InUCHIGATA ET AL .
FIGURE 2 .
￿
Binding of antibody E5C2 to untreated and neuraminidase-treated glycolipids
separated by thin-layer chromatography. Glycolipid isolation, thin-layer chromatography,
neuraminidase treatment, and immunostaining were performed as described in Materialsand
Methods . After thin-layer chromatography, the glycolipids were either not treated (A, C, and
E) or treated with neuraminidase (B, D, and F) before immunostaining with E5C2 . (A andB)
Glycolipids isolated from 4 X 106 RINm5F cells; (C and D) glycolipids isolated from 2 X 10 6
HL-60 cells; (E and F) ganglioside-enriched preparation from human RBCs. Globoside(GLO)
and ganglioside GM, (GMI) were used as chromatographic standards .
( Antibody Dilution
FIGURE 3 .
￿
Binding of various dilutions of antibody E5C2 to HL-60 glycolipids . Glycolipids
were extracted from HL-60 cells and the RIA was performed as described in Materials and
Methods . Each well of the microtiter plate was coated with glycolipids isolated from 10,000
HL-60 cells .
contrast, culture supernatant from the myeloma fusion partner (No . 653) failed
to bind . Taken together, these experiments argue that E5C2 recognizes a
carbohydrate antigen on neutral glycolipids and that this antigen is hidden by
covalently bound sialic acid residues .
The pattern of antibody binding in Fig . 2 was similar to that previously seen
with another mAb, anti-My-28 (13) . This suggested that E5C2 might recognize
a sequence in the glycolipid paragloboside . Paragloboside was purified and tested
by the immunostaining method (Fig. 4) . By this technique, E5C2 could detect 5
ng of pure glycolipid (Fig . 4B). RIA was even more sensitive and E5C2 could
detect as little as 1 ng of pure paragloboside (Fig . 5) . Several other pure132 CVTOTOXIC ANTI-ISLET CELL MONOCLONAL ANTIBODY
FIGURE 4.
￿
Binding ofantibody E5C2 to glycolipids separated by thin-layer chromatography .
Immunostaining of the thin-layer chromatogram wasperformed as described in Materialsand
Methods . (A-H) Pure paragloboside (A) 1 ng; (B) 5 ng; (C) 10 ng; (D)20 ng: (E) 60 ng; (F)
120 ng ; (G) 240 ng ; (H) 600 ng ; (1) glycolipids isolated from 2 x 106 HL-60 cells . The
chromatographic standards were the same as those used in Fig. 2 . (GLO) globoside ; (GMI)
ganglioside GM, .
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FIGURE 5 .
￿
Binding of antibody E5C2 to purified paragloboside . The RIAwasperformed as
described in Materialsand Methods .
glycolipids were also tested by RIA including lactosyl ceramide, ceramide tri-
hexoside, facto-N-fucopentaosyl III ceramide, H, blood group active glycolipid,
asialo GM I , and (a2-3) and (a2-6) sialosylparagloboside . E5C2 did not bind to
200 ng ofany of these giycolipids (Table IV). Interestingly, although E5C2 did
not bind to (a2-3) or (a2-6) sialosylparagloboside, the E5C2 antigen was revealed
after removal of the sialic acid from these glycolipids by neuraminidase (Table
IV).
The specificity of antibody E5C2 for the sugar sequence found in paraglobo-
side was further studied by hapten inhibition and adsorption studies . The best
inhibitor tested was N-acetyllactosamine (Galß1-4GicNAc), which is the nonre-TABLE IV
RIA ofBinding ofAntibody E5C2 to Untreated andNeuraminidase-treated Pure Glycolipids
D
D
+
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FIGURE 6.
￿
Inhibition of E5C2 bindingto glycolipids by definedcarbohydrates. The antibody
was absorbed with various defined sugars and the RIAs were performed as described in
Materials and Methods. Microtiter wells were coated with glycolipids isolated from 2 x 106
HL-60 cells. When no inhibiting sugar was present, ^-3,000 cpm of "'iodine-labeled second
antibody bound to the well. The resultswith lactobionic acid are not shown, but it gave 50%
inhibition at aconcentrationof -200 mM.
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ducing terminal disaccharide of paragloboside (Fig. 6). Lactose and lactulose
were reasonable inhibitors but were ^'20-30 times less effective. At the concen-
trations tested, the only carbohydrates that demonstrated any inhibition either
had a terminal galactose in the # position or couldassume a# configuration (free
galactose). The fine specificity was also examined by adsorption studies with
Synsorbs (Table V). These studies indicate that galactose-linked ,Q1-4 to N-
acetylglucosamine (as occurs in paragloboside) is an excellent inhibitor, while
little or no inhibition is seen when the linkage is #1-3.
WesternBlot Analysis.
￿
Extracts ofRINm5F cells were subjected toSDS-PAGE
and Western blotting. The results of immunostaining such blots are seen in Fig.
7. E5C2 specifically stained two bands, but only in neuraminidase-treated blots
of the RINm5F cell extract (lane A). These bands had molecular weights of
60,000 and 68,000 . Untreatedblots ofthe RINm5F cell extract were notstained
by E5C2 (lane E). Treated or untreated blots of GH3 cell extract were not
stained (data not shown). The supernatant of the myeloma fusion partner (No.
653) also did not specifically stain any bands (lanes D and F). Lactose (200 mM)
blocked E5C2 binding (lane B) while glucose at the same concentration did not
Gl colipid Structure
E5C2 binding
Lactosyl ceramide Gal#1-4GIco1-1'cer -
Untreated*
Neur
dase
tNN
Ceramide trihezoside Gala I-4Gal01-4GIcft1-I'cer -
Paragloboside Gal,6I-4GIcNAcs1-3Galpl-4GIcs1-I'cer +
Lacto-N-fucopentaosyl III ceramide Galol-4GIcNAcp1-3Ga1#1-4GIc#1-1'cer -
Fucal-3
H, Fucal-2Gal#1-4GIcNAc$1-3Gal#1-4GIcft1-1'cer -
NAsialo GM r Galpl-3GaINAc#I-4Galft1-4Glcp1-1'cer -
N(a2-3)sialosylparagloboside NeuAca2-3Ga1P1-4GIcNAcs1-3Galpl-4GIcft1-1'cer -
(a2-6)sialosylparagloboside NeuAca2-6Ga1~1-4GIcNAcs1-3Galsl-4GIc#1-I'cer - +
* At least 200 ng of each glycolipid were tested134 CYTOTOXIC ANTI-ISLET CELL MONOCLONAL ANTIBODY
TABLE V
Gal#1-4GlcNAc, but not Gal#]-3GlcNAc, Inhibits E5C2 Binding:
Immunoadsorption Studies with Solid-Phase Synthetic Carbohydrate
Haptens
FIGURE 7 .
￿
Western blot analysis of binding of antibody E5C2 to RINm5F cell extract.
Immunoblots ofRINm5F cell extract were prepared as described in Materials and Methods .
Each lane contained 100 ug of protein . Blots were exposed to neuraminidase (A-D) or buffer
(E andF) before incubation with antibody . Antibody E5C2 was preincubated with 200mM
lactose (B) or glucose (C) . 653 is the supernatant of the myeloma fusion partner . Mol wt X
10' shown at left .
Hapten '2'1-Bound (cpm t SD) Percent inhi-
bition
None 4107 ± 225 -
Glc 3961 t 180 4
Gal,B1-4GIcNAc 1182 ± 300 71
Gal#1-3GIcNAc 3958 ± 218 4UCHIGATA ET AL.
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(Fig. 7 lane C). When intact viable RINm5F cells were treated with neuraminidase
before extraction, blots of these extracts immunostained with E5C2 displayed a
pattern similar to that seen with blots of RINm5F cell extract treated with
neuraminidase after blotting (data not shown). The bands were of slightly lower
molecular weight (^1,000) presumably due to removal of sialic acid residues
before SDS-PAGE.
Inhibition of E5C2 Binding to Viable Cells by Lactose.
￿
Since lactose inhibited
E5C2 binding to glycolipid antigens (Fig. 6) and to RINm5F cell glycoproteins
(Fig. 7), its effect on antibody binding to intact cells was examined. By indirect
immunofluorescence, 200 mM lactose blocked binding of E5C2 to neuramini-
dase-treated RINm5F cells and neuraminidase-treated primary islet cells (Table
II). Lactose also blocked E5C2 binding to untreated RINm5F cells (data not
shown). These results strongly indicate that lactose inhibits E5C2 binding to the
intact cellular antigenic determinants. Taken together, these studies show that
the E5C2 antigen is a carbohydrate moiety on cell surface glycoproteins.
Discussion
E5C2 is a rat IgMic monoclonal anti-islet cell autoantibody that is specifically
cytotoxic for RINm5F cells and for neuraminidase-treated isolated primary islet
cells. By indirect immunofluorescence, neuraminidase increased E5C2 binding
not only to RINm5F cells but also to primary islet cells. Since neuraminidase
removes sialic acid residues from glycoconjugates, our studies indicate that the
E5C2 antigenic determinants are partially exposed in RINm5F cells and are
hidden by sialic acid residues in normal islet cells. This suggests that E5C2 may
recognize a glycoconjugate antigen. In fact, E5C2 binds to glycolipids separated
on thin-layer chromatography both before and after treatment with neuramini-
dase (Fig. 2). We elucidated the structure of the antigenic determinants as
follows. E5C2 directly binds only to paragloboside (Gal0l-4GlcNAc#1-3Ga1(01-
4Glc-ceramide) and higher polylactosamine-containing structures, but not to
related glycolipids (Table IV). Both lactose (GaloI-4Glc) and N-acetyllactosamine
(Gal01-4G1cNAc) inhibit E5C2 binding to its antigen, although lactose is 20-30
times less effective. In addition, Gall-3G1cNAc is ineffective as an inhibitor
(Table V); E5C2 did not bind to asialo GM, (Table IV), or to any carbohydrates
that had a terminal galactose with an a linkage (Fig. 6). These results indicate
that a #I -4-linked terminal galactose is a critical part of the antigenic determinant.
Our experiments argue that E5C2 antigen in RINm5F cells is not linked to a
glycolipid (Fig. 2) but, as shown by Western blots, to a glycoprotein (Fig. 7).
These antigens were revealed by treating blots with neuraminidase. E5C2 bind-
ing to the neuraminidase-treated glycoproteins was blocked by lactose but not
by glucose, indicating that the carbohydrate determinant on the glycoprotein is
similar to that found on the glycolipids. Based on these results, the probable
carbohydrate structure on these glycoproteins is NeuAca2-3/6Gal#1-4G1cNAc-
R. After neuraminidase removes the sialic acid (NeuAc), E5C2 binds to the
underlying structure . Since lactose inhibited binding of E5C2 to RINm5F cells
and normal rat islets, as determined by immunofluorescence, this suggests that
the antibody recognizes this carbohydrate antigen on intact cells. Thus, antibody
E5C2 recognizes a carbohydrate moiety on cell surface glycoconjugates. With136
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RINm5F cells these antigenic determinants were found on glycoproteins with
molecular weights of 60,000 and 68,000 but not on glycolipids. Baekkeskov et
al. (7, 8) reported that sera from newly diagnosed IDDM patients and BB rats
have autoantibodies to a 64,000 mol wt islet protein. It is not known whether
these serum antibodies bind to the same proteins recognized by E5C2 or what
roles the E5C2 glycoproteins play in the pathogenesis of IDDM . This is now
under investigation.
Antibodies recognizing lacto-N-neotetraose (Gal#I-4GlcNAc#1-3Gal#I-4Glc)
or its glycosphingolipid analogue, paragloboside, have been described previously
(13, 32, 33). Recently, antilipid antibodies were measured in normal and patho-
logic human sera by means of a microplate method of complement-mediated
immune lysis of fluorescent dye-trapped liposomes (34). No antibodies were
observed against paragloboside in 11 healthy adult sera. High titers of these
antibodies were found in some patients with idiopathic thrombocytopenic pur-
pura, SLE, liver diseases, lymphoma, and leukemia. Cell surface sialic acids can
occupy terminal positions on carbohydrate chains and neuraminidase may re-
move sialic acids, revealing carbohydrate structures not normally seen by the
immune system of normal individuals. Neuraminidase is known to be present in
many microorganisms and in mammalian cell lysosomes (35). It is possible that
pathological conditions caused by certain bacterial and viral infections or by
chemical inflammatory agents mayremove sialic acid residues, exposing normally
hidden autoantigens. Similarly, defective protein glycosylation, which may be
genetically linked to the H-2 locus (36), could result in the expression of normally
cryptic autoantigens. These observations raise the possibility that exposure of
hidden antigenic determinants may trigger and be the target of autoimmune
attack.
Summary
To investigate the autoimmune pathogenesis of spontaneously occurring dia-
betes mellitus in BB rats, spleen cells of newly diagnosed diabetic 1113 rats were
fused with mouse myeloma cells. Hybridoma supernatants were screened for
antibodies by indirect immunofluorescence and by 5'Cr-release assays using the
RINm5F rat insulinoma cell line. One clone, E5C2, produced an IgMK antibody
that was cytotoxic for RINm5F cells, but not for other rat cell lines nor for
primary rat islet cells. However, treatment of primary rat islet cells with neura-
minidase exposed surface antigens and rendered the cells susceptible to comple-
ment-mediated lysis by antibody E5C2. Using immunostaining of glycolipids
separated by thin-layer chromatography, hapten inhibition assays with defined
carbohydrates, and Western blots, the antigens recognized by E5C2 on RINm5F
cells were identified as glycoproteins with molecular weights of 60,000 and
68,000. The antibody recognizes a carbohydrate antigen containing the sequence
Gal#1-4G1cNAc-R, which on RINm5F cells is predominantly hidden by cova-
lently bound sialic acid. These studies raise the possibility that hidden antigenic
determinants on islet cells exposed by a variety of means may be the target of
autoimmune attack.We thank Dr. Daniel Drell for arranging the supply of BB rats and Mrs. Eloise Mange
and Ms. Val Rementer for skillfully preparing the manuscript.
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